"It is hoped that the completion of clinical trials of the Red and White Vaccine can be used for the fourth dose."
The main researcher for the Red and White Vaccine at Airlangga University (Unair) Prof Fedik Abdul Rantam said the Red and White Vaccine research team is preparing to use the Red and White Vaccine for the fourth dose of Covid-19 vaccination in Indonesia.
"It is hoped that the clinical trial of the Red and White Vaccine can be used for the fourth dose," said Fedik Abdul Rantam in Jakarta, Monday (11/7/2022).
The Covid-19 vaccine, which was developed since May 12, 2020, is going through a third phase of clinical trials starting June 28, 2022. The research team has collected 1,100 volunteers from a total of 4,005 volunteers needed for clinical trial subjects, which includes one group of volunteers receiving the comparison vaccine and two groups of volunteers. recipient of the Red and White Vaccine.
"The phase 3 clinical trial process is ongoing. So far the results are good. Currently, only 1,100 volunteers have been recruited," said Fedik.
The reaction to giving vaccines to volunteers in the third phase of clinical trials was observed at Dr Soetomo Hospital Surabaya, Unair Hospital (RS), Saiful Anwar Hospital Malang, Jember Pulmonary Hospital, and Subandi Hospital Jember.
The third phase clinical trial of the Red and White Vaccine developed at Airlangga University is targeted to last a maximum of six months after the second dose of vaccine is injected.
The Covid-19 vaccine is targeted to start production by the end of 2022, after obtaining an emergency use permit from the Food and Drug Supervisory Agency (BPOM).
Head of the Red and White Vaccine Clinical Test Team Unair Dominic Husada said the use of the Red and White Vaccine for booster vaccination could only be carried out after further clinical trials were carried out.
"Currently it is in phase 3. After that, it is submitted for a distribution permit from BPOM. Only then will further clinical trials be carried out for boosters," he said. (Among)
